In late July 2026, Pfizer reported positive Phase 3 results for its oral JAK3/TEC inhibitor LITFULO in nonsegmental vitiligo and secured European Commission approval for its 2026–2027 XFG‑adapted ...
Source LinkIn late July 2026, Pfizer reported positive Phase 3 results for its oral JAK3/TEC inhibitor LITFULO in nonsegmental vitiligo and secured European Commission approval for its 2026–2027 XFG‑adapted ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.